Changing Treatment Protocol From Azathioprine to Mycophenolate Mofetil: Decrease in Renal Dysfunction, Increase in Infections

Transplantation Proceedings

Volumn 39, Issue 4, 2007, Pages 1237-1240

  Pourfarziani, V ^a   Panahi, Y ^a   Assari, S ^a   Moghani Lankarani, M ^a   Saadat, S H ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HOSPITAL READMISSION; HUMAN; INFECTION; INTENSIVE CARE UNIT; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

AZATHIOPRINE; COHORT STUDIES; COMMUNICABLE DISEASE CONTROL; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; PATIENT READMISSION; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS; TREATMENT FAILURE;

EID: 34248559645     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.03.006     Document Type: Article

References (26)

1. Abbott K.C., Hypolite I.O., Viola R., et al. Hospitalizations for cytomegalovirus disease after renal transplantation in the United States. Ann Epidemiol 12 (2002) 402
2. Hakemi M., Shahebrahimi K., Ganji M.R., et al. Side effects of mycophenolate mofetil versus azathioprine in iranian renal transplant recipients (single-center experience). Transplant Proc 34 (2002) 2091
3. Srinivas T.R., Kaplan B., Schold J.D., et al. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. Transplantation 80 2 suppl (2005) S211
4. Attallah N., Goggins M., Nori U., et al. Comparison of long-term actual renal allograft survival in mycophenolate mofetil and azathioprine-based triple drug immunosuppression protocols. Transplant Proc 37 (2005) 2060
5. Gentil M.A., Gonzalez-Roncero F., Cantarell C., et al. Effect of new immunosuppressive regimens on cost of renal transplant maintenance immunosuppression. Transplant Proc 37 (2005) 1441
6. Schnitzler M.A., Woodward R.S., Lowell J.A., et al. Ten-year cost effectiveness of alternative immunosuppression regimens in cadaveric renal transplantation. Transplant Proc 31 3B suppl (1999) 19S
7. Dispute Over Inflation Rate. Iran Daily (2006). http://www.iran-daily.com/1385/2695/html/focus.html 6-7: Tue, Oct 31, Available at: http://www.iran-daily.com/1385/2695/html/focus.html
8. Roshandel D, Rezailashkajani M, Shafaee S, et al: A cost analysis of functional bowel disorders in Iran. Int J Colorectal Dis (in press)
9. Wuthrich R.P., Weinreich T., Ambuhl P.M., et al. Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil. Nephrol Dial Transplant 14 (1999) 394
10. Fritsche L., Sperschneider H., Budde K., et al. Conversion to mycophenolate mofetil for chronic progressive deterioration of renal allograft function: first clinical experiences in 44 patients. Transplant Proc 30 (1998) 1190
11. Mele T.S., and Halloran P.F. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 47 (2000) 215
12. Woodroffe R., Yao G.L., Meads C., et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess 9 (2005) 1
13. Bernabeu-Wittel M., Naranjo M., Cisneros J.M., et al. Infections in renal transplant recipients receiving mycophenolate versus azathioprine-based immunosuppression. Eur J Clin Microbiol Infect Dis 21 (2002) 173
14. Schnitzler M.A., Craig K.E., Hardinger K.E., et al. Mycophenolate mofetil is associated with less death with function than azathioprine in cadaveric renal transplantation. Nephrol Dial Transplant 18 (2003) 1197
15. David K.M., Morris J.A., Steffen B.J., et al. Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin Transplant 19 (2005) 279
16. Kobashigawa J.A., Tobis J.M., Mentzer R.M., et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant 6 5 Pt 1 (2006) 993
17. Miladipour A.H., Ghods A.J., and Nejadgashti H. Effect of mycophenolate mofetil on the prevention of acute renal allograft rejection. Transplant Proc 34 (2002) 2089
18. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345 (1995) 1321
19. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric kidney transplantation. Transplantation 61 (1996) 1029
20. The U.S. Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. Transplant Proc 29 (1997) 348
21. Prokopenko E.I., Shcherbakova E.O., Vatazin A.V., et al. Infectious complications in using mofetil micofenolate in patients with renal allotransplant. Ter Arkh 77 (2005) 67
22. Ter Meulen C.G., Wetzels J.F.M., and Hilbrands L.B. The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrol Dial Transplant 15 (2000) 711
23. Sarmiento J.M., Munn S.R., Paya C.V., et al. Is cytomegalovirus infection related to mycophenolate mofetil after kidney transplantation?. A case-control study. Clin Transplant 12 (1998) 371
24. Giral M., Nguyen J.M., Daguin P., et al. Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction. J Am Soc Nephrol 12 (2001) 1758
25. Sarmiento J.M., Dockrell D.H., Schwab T.R., et al. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 14 (2000) 136
26. Munoz M.A., Andres A., Gallego R., et al. Mycophenolate mofetil immunosuppressive therapies increase the incidence of cytomegalovirus infection in renal transplantation. Transplant Proc 34 (2002) 97